NCT01861340 - Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

July 31, 2016

Conditions

Myeloma

Interventions

DRUG

Lenalidomide, Dexamethasone, and MEDI-551

Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.

Trial Locations (1)

21287

The Sidney Kimmel Comprehensive Cancer Center, Baltimore